Mercier Johanna
Chief Comm & Corp Aff Officer
In the last 12 months, Mercier Johanna filed 50 SEC Form 4 transactions across 1 issuer: $0 in open-market purchases and $18.5M in open-market sales. 40% of these transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $18.5MOpen-market sells (1y)
- 50Transactions filed
- 1Distinct issuers
- 40%Under Rule 10b5-1
- 2026-09-15Latest filing
Issuers Filed For By open-market buy volume
Recent Form 4 Filings Most recent 50 of 50 (1-year window)
| Date | Ticker | Company | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $229.9K | 1,600 | $143.7 |
| 2026-09-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $115.6K | 800 | $144.5 |
| 2026-09-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $87.2K | 600 | $145.3 |
| 2026-09-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 2,797 | – |
| 2026-09-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 2,797 | – |
| 2026-09-10 | GILD | GILEAD SCIENCES, INC. | Other | F | $195.1K | 1,347 | $144.8 |
| 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Exercise 10b5-1 | M | $1.5M | 23,110 | $66.6 |
| 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Exercise 10b5-1 | M | $136.7K | 1,890 | $72.3 |
| 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Exercise 10b5-1 | M | $0 | 23,110 | $0.0 |
| 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Exercise 10b5-1 | M | $0 | 1,890 | $0.0 |
| 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $2.3M | 16,530 | $137.4 |
| 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.6M | 11,470 | $138.0 |
| 2026-07-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $389.8K | 3,000 | $129.9 |
| 2026-06-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $182.7K | 1,480 | $123.4 |
| 2026-06-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $132.7K | 1,070 | $124.0 |
| 2026-06-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $56.4K | 450 | $125.4 |
| 2026-06-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 2,796 | – |
| 2026-06-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 2,796 | – |
| 2026-06-10 | GILD | GILEAD SCIENCES, INC. | Other | F | $162.9K | 1,341 | $121.5 |
| 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Exercise 10b5-1 | M | $1.7M | 25,000 | $66.6 |
| 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Exercise 10b5-1 | M | $0 | 25,000 | $0.0 |
| 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.0M | 7,749 | $130.3 |
| 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.5M | 11,177 | $131.2 |
| 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.1M | 8,374 | $132.2 |
| 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $92.9K | 700 | $132.8 |
| 2026-04-15 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $422.9K | 3,000 | $141.0 |
| 2026-03-16 | GILD | GILEAD SCIENCES, INC. | Sell | – | $432.7K | 3,000 | $144.2 |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 6,617 | – |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $477.8K | 3,216 | $148.6 |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 6,617 | – |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 9,590 | – |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 35,880 | $0.0 |
| 2026-02-27 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 11,090 | $0.0 |
| 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Grant | – | $1.7M | 25,000 | $66.6 |
| 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 25,000 | $0.0 |
| 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Sell | – | $2.8M | 18,405 | $154.2 |
| 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Sell | – | $1.5M | 9,395 | $154.9 |
| 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Sell | – | $31.1K | 200 | $155.6 |
| 2026-02-03 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 44,867 | $0.0 |
| 2026-02-03 | GILD | GILEAD SCIENCES, INC. | Grant | – | $3.6M | 24,800 | $143.3 |
| 2026-01-15 | GILD | GILEAD SCIENCES, INC. | Sell | – | $372.9K | 3,000 | $124.3 |
| 2025-12-15 | GILD | GILEAD SCIENCES, INC. | Sell | – | $366.0K | 3,000 | $122.0 |
| 2025-12-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 3,842 | – |
| 2025-12-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $220.1K | 1,814 | $121.3 |
| 2025-12-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 3,842 | – |
| 2025-11-17 | GILD | GILEAD SCIENCES, INC. | Grant | – | $1.7M | 25,000 | $66.6 |
| 2025-11-17 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 25,000 | $0.0 |
| 2025-11-17 | GILD | GILEAD SCIENCES, INC. | Sell | – | $3.2M | 25,524 | $125.8 |
| 2025-11-17 | GILD | GILEAD SCIENCES, INC. | Sell | – | $312.6K | 2,476 | $126.3 |
| 2025-10-15 | GILD | GILEAD SCIENCES, INC. | Sell | – | $354.2K | 3,000 | $118.1 |
Methodology & FAQ
How These Filings Are Sourced
All transactions on this page are sourced directly from SEC EDGAR. A complete description of the open-market vs grant distinction, the Rule 10b5-1 plan-reference heuristic, and the per-insider name matching is documented in the Methodology.
What companies does Mercier Johanna file Form 4 disclosures for?
Mercier Johanna has filed SEC Form 4 transactions for 1 issuer in the last 12 months: GILEAD SCIENCES, INC. (GILD).
What does the 10b5-1 badge mean on these transactions?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Of Mercier Johanna's 50 reported transactions in the last 12 months, 20 (40%) reference a 10b5-1 trading plan in the Form 4 footnotes.
Are these all the transactions Mercier Johanna has executed?
This page shows SEC Form 4 transactions on record in Pactolio's tracked universe for the last 12 months. Form 4 only covers transactions in registered classes of equity at issuers where the person qualifies as an insider (officer, director, or 10% beneficial owner). Trades in funds, foreign issuers, or non-insider positions are not disclosed under Form 4 and are not included here.